Coherus Oncology, Inc. (CHRS) shareholders
Close on Nov 17, 2026Market cap $73.93MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 12,750,800 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 8,934,952 | 5.80% | 13G (passive) | Jun 30, 2026 |
| Evgeny Zaytsev ("Zaytsev") Joint filing with Philip Sawyer ("Sawyer") (6.50%) | 7,602,708 | 6.50% | 13G (passive) | Sep 5, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CHRS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 13,050,623 | 8.45% | $18.27M | +759,823 | 3.58% |
| BlackRock, Inc. | 12,003,316 | 7.77% | $16.80M | +1,638,242 | 0.00% |
| Vanguard Capital Management LLC | 5,949,490 | 3.85% | $8.33M | +496,728 | 0.00% |
| Geode Capital Management, LLC | 3,685,567 | 2.39% | $5.16M | +563,989 | 0.00% |
| Samsara BioCapital, LLC | 3,428,571 | 2.22% | $4.80M | – | 0.39% |
| Kohlberg Kravis Roberts & Co. L.P. | 3,036,076 | 1.97% | $4.18M | – | 0.07% |
| State Street Corp | 2,382,305 | 1.54% | $3.34M | +56,446 | 0.00% |
| Two Sigma Investments, LP | 2,259,412 | 1.46% | $3.16M | −42,589 | 0.00% |
| CM Management, LLC | 2,100,000 | 1.36% | $2.94M | – | 1.96% |
| C WorldWide Group Holding A/S | 1,928,464 | 1.25% | $2.70M | – | 0.07% |
| Alyeska Investment Group, L.P. | 1,733,234 | 1.12% | $2.43M | −516,766 | 0.01% |
| Hudson Bay Capital Management LP | 1,693,000 | 1.10% | $2.37M | −11,980 | 0.01% |
| Aqr Capital Management LLC | 1,330,201 | 0.86% | $1.86M | +124,155 | 0.00% |
| Charles Schwab Investment Management Inc | 1,228,069 | 0.79% | $1.72M | +72,168 | 0.00% |
| Panagora Asset Management Inc | 1,137,325 | 0.74% | $1.59M | −321,985 | 0.00% |
| Northern Trust Corp | 1,129,470 | 0.73% | $1.58M | +215,670 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,015,991 | 0.66% | $1.42M | +66,072 | 0.00% |
| Nomura Asset Management International Inc. | 899,999 | 0.58% | $1.26M | – | 0.00% |
| Vanguard Portfolio Management LLC | 883,454 | 0.57% | $1.24M | +278,929 | 0.00% |
| UBS Group AG | 760,358 | 0.49% | $1.06M | +213,149 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 147 | 70M | 45.5% | 11 / 62 | 42 / 20 | 6M | 7M |
| Q1 2026 | 158 | 72M | 46.3% | 42 / 47 | 37 / 10 | 28M | 4M |
| Q4 2025 | 128 | 57M | 37.1% | 26 / 39 | 33 / 8 | 11M | 5M |
| Q3 2025 | 114 | 52M | 33.5% | 21 / 37 | 30 / 17 | 2M | 6M |
| Q2 2025 | 112 | 56M | 36.0% | 15 / 33 | 33 / 20 | 3M | 9M |
| Q1 2025 | 117 | 62M | 40.1% | 13 / 41 | 31 / 18 | 6M | 10M |
| Q4 2024 | 124 | 66M | 42.5% | 31 / 30 | 34 / 35 | 10M | 22M |
| Q3 2024 | 128 | 77M | 50.1% | 17 / 41 | 32 / 22 | 19M | 13M |
| Q2 2024 | 135 | 83M | 53.7% | 24 / 47 | 36 / 24 | 8M | 14M |
| Q1 2024 | 137 | 88M | 57.2% | 23 / 39 | 55 / 42 | 22M | 18M |
| Q4 2023 | 156 | 85M | 54.9% | 32 / 48 | 54 / 42 | 18M | 26M |
| Q3 2023 | 169 | 94M | 60.9% | 42 / 64 | 47 / 33 | 23M | 15M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
110 funds held CHRS in Q2 2026, 63% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CHRS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,953,617 | 2.56% | $5.54M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,217,678 | 2.08% | $4.50M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,863,589 | 1.21% | $2.61M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,422,262 | 0.92% | $2.01M | 0.01% | Jul 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 927,830 | 0.60% | $1.48M | 0.03% | May 29, 2026 |
| Nomura Healthcare Fund | 900,000 | 0.58% | $1.26M | 0.17% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 783,155 | 0.51% | $1.25M | 0.00% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 741,539 | 0.48% | $1.04M | 0.01% | Jun 30, 2026 |
| Schwab U.S. Small-Cap ETF | 709,098 | 0.46% | $1.13M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 535,033 | 0.35% | $850.70K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 438,059 | 0.28% | $613.28K | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 436,778 | 0.28% | $611.49K | 0.00% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 318,186 | 0.21% | $448.64K | 0.01% | Jul 31, 2026 |
| Master Small Cap Index Series | 274,247 | 0.18% | $383.95K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 267,846 | 0.17% | $425.88K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dennis M. Lanfear | President & CEO, Director | 1,567,884 | 1.01% | Jun 2, 2026 |
| Bryan J. McMichael | Chief Financial Officer | 133,736 | 0.09% | Jun 2, 2026 |
| Paul Reider | Chief Commercial Officer | 82,069 | 0.05% | Jan 22, 2025 |
| Ali J. Satvat | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Lee Nisley Newcomer | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Jill O'Donnell-Tormey | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Charles W. Newton | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Rita A. Karachun | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Mats Wahlstrom | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Michael Lee Ryan | Director | 30,000 | 0.02% | Jun 9, 2026 |
| Georgia Erbez | Director | – | – | Jun 13, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Lee Ryan Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Mats Wahlstrom Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Ali J. Satvat Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Jill O'Donnell-Tormey Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Lee Nisley Newcomer Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Rita A. Karachun Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Charles W. Newton Director | Jun 5, 2026 | Award | +30,000 | – | – | 30,000 |
| Dennis M. Lanfear President & CEO, Director | Jan 23, 2026 | Award | +375,000 | – | – | 1,048,235 |
| Bryan J. McMichael Chief Financial Officer | Jan 22, 2026 | Award | +112,500 | – | – | 133,736 |
| Dennis M. Lanfear President & CEO, Director | Jan 20, 2026 | Tax withholding | −11,839 | $1.55 | $18.35K | 673,235 |
| Bryan J. McMichael Chief Financial Officer | Jan 20, 2026 | Tax withholding | −1,715 | $1.55 | $2.66K | 21,236 |
| Mats Wahlstrom Director | May 23, 2025 | Sale | −99,988 | $0.74 | $73.99K | 0 |
| Dennis M. Lanfear President & CEO, Director | Jan 20, 2025 | Tax withholding | −11,810 | $1.39 | $16.42K | 685,074 |
| Bryan J. McMichael Chief Financial Officer | Jan 20, 2025 | Tax withholding | −1,711 | $1.39 | $2.38K | 22,951 |
| Paul Reider Chief Commercial Officer | Jan 20, 2025 | Tax withholding | −4,858 | $1.39 | $6.75K | 82,069 |
| Bryan J. McMichael Chief Financial Officer | Jan 7, 2025 | Tax withholding | −1,711 | $1.57 | $2.69K | 24,662 |
| Dennis M. Lanfear President & CEO, Director | Jan 4, 2025 | Tax withholding | −11,810 | $1.66 | $19.60K | 696,884 |
| Paul Reider Chief Commercial Officer | Jan 4, 2025 | Tax withholding | −2,277 | $1.66 | $3.78K | 86,927 |
| Paul Reider Chief Commercial Officer | Dec 13, 2024 | Tax withholding | −2,073 | $1.61 | $3.34K | 89,204 |
| Mats Wahlstrom Director | Feb 9, 2024 | Gift | +99,988 | – | – | 99,988 |
| Mats Wahlstrom Director | Feb 9, 2024 | Gift | −99,988 | – | – | 0 |
| Mats Wahlstrom Director | Feb 1, 2024 | Option exercise | +44,991 | $1.67 | $75.13K | 99,988 |
| Mats Wahlstrom Director | Feb 1, 2024 | Option exercise | +14,997 | $1.67 | $25.04K | 54,997 |
| Paul Reider Chief Commercial Officer | Jan 20, 2024 | Tax withholding | −4,854 | $2.44 | $11.84K | 81,277 |
| Dennis M. Lanfear President & CEO, Director | Jan 20, 2024 | Tax withholding | −11,218 | $2.44 | $27.37K | 708,694 |
| Bryan J. McMichael See Remarks | Jan 20, 2024 | Tax withholding | −1,707 | $2.44 | $4.17K | 22,972 |
| Bryan J. McMichael See Remarks | Jan 7, 2024 | Tax withholding | −1,707 | $2.87 | $4.90K | 24,679 |
| Paul Reider Chief Commercial Officer | Jan 4, 2024 | Tax withholding | −2,275 | $2.92 | $6.64K | 86,131 |
| Dennis M. Lanfear President & CEO, Director | Jan 4, 2024 | Tax withholding | −11,781 | $2.92 | $34.40K | 719,912 |
| McDavid Stilwell Chief Financial Officer | Dec 31, 2023 | Tax withholding | −18,440 | $3.33 | $61.41K | 75,305 |
| Paul Reider Chief Commercial Officer | Dec 13, 2023 | Tax withholding | −2,049 | $2.37 | $4.86K | 88,406 |
| Dennis M. Lanfear President & CEO, Director | Nov 22, 2023 | Option exercise | +258,940 | $1.42 | $367.69K | 954,793 |
| Dennis M. Lanfear President & CEO, Director | Nov 22, 2023 | Sale | −223,100 | $2.02 | $450.66K | 731,693 |
| Dennis M. Lanfear President & CEO, Director | Nov 22, 2023 | Option exercise | +41,000 | $1.42 | $58.22K | 695,853 |
| McDavid Stilwell Chief Financial Officer | Apr 1, 2023 | Tax withholding | −3,457 | $6.84 | $23.65K | 102,252 |
| Paul Reider Chief Commercial Officer | Apr 1, 2023 | Tax withholding | −2,451 | $6.84 | $16.76K | 87,053 |
| Vladimir Vexler Chief Scientific Officer | Mar 31, 2023 | Tax withholding | −16,278 | $6.84 | $111.34K | 116,361 |
| Bryan J. McMichael See Remarks | Jan 20, 2023 | Award | +12,500 | – | – | 26,386 |
| McDavid Stilwell Chief Financial Officer | Jan 20, 2023 | Award | +40,000 | – | – | 104,243 |
| Vladimir Vexler Chief Scientific Officer | Jan 20, 2023 | Award | +40,000 | – | – | 131,323 |
| Dennis M. Lanfear President & CEO, Director | Jan 20, 2023 | Award | +86,250 | – | – | 654,853 |
| Vladimir Vexler Chief Scientific Officer | Jan 11, 2023 | Tax withholding | −3,602 | $10.26 | $36.96K | 91,323 |
| Vladimir Vexler Chief Scientific Officer | Jan 10, 2023 | Tax withholding | −3,602 | $9.85 | $35.48K | 94,925 |
| Bryan J. McMichael See Remarks | Jan 7, 2023 | Tax withholding | −1,699 | $9.58 | $16.28K | 13,886 |
| Vladimir Vexler Chief Scientific Officer | Jan 4, 2023 | Tax withholding | −5,437 | $9.87 | $53.66K | 98,527 |
| McDavid Stilwell Chief Financial Officer | Jan 4, 2023 | Tax withholding | −5,437 | $9.87 | $53.66K | 64,243 |
| Dennis M. Lanfear President & CEO, Director | Jan 4, 2023 | Tax withholding | −10,905 | $9.87 | $107.63K | 568,603 |
| Dennis M. Lanfear President & CEO, Director | Dec 30, 2022 | Gift | −4,000 | – | – | 432,684 |
| McDavid Stilwell Chief Financial Officer | Apr 1, 2022 | Tax withholding | −3,458 | $12.85 | $44.44K | 69,680 |
| Vladimir Vexler Chief Scientific Officer | Apr 1, 2022 | Tax withholding | −3,458 | $12.85 | $44.44K | 103,963 |
| Mats Wahlstrom Director | Feb 28, 2022 | Award | +29,994 | $2.08 | $62.39K | 40,000 |
| Mats Wahlstrom Director | Feb 25, 2022 | Award | +10,006 | $11.64 | $116.47K | 10,006 |
| Vladimir Vexler Chief Scientific Officer | Jan 11, 2022 | Tax withholding | −3,583 | $14.36 | $51.45K | 107,421 |
| Vladimir Vexler Chief Scientific Officer | Jan 10, 2022 | Tax withholding | −4,150 | $14.30 | $59.35K | 111,004 |
| Dennis M. Lanfear President & CEO, Director | Jan 4, 2022 | Award | +86,250 | – | – | 579,508 |
| Vladimir Vexler Chief Scientific Officer | Jan 4, 2022 | Award | +40,000 | – | – | 115,154 |
| McDavid Stilwell Chief Financial Officer | Jan 4, 2022 | Award | +40,000 | – | – | 73,138 |
| Dennis M. Lanfear President & CEO, Director | Nov 17, 2021 | Gift | −10,000 | – | – | 436,684 |
| McDavid Stilwell Chief Financial Officer | Oct 15, 2021 | Sale | −3,507 | $16.80 | $58.92K | 31,611 |
| James Healy Director | Sep 29, 2021 | Sale | −286,076 | $16.12 | $4.61M | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Coherus Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 53,406 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Dennis M. Lanfear Officer | Nov 22, 2023 | 223,100 | $449.78K | Nov 22, 2023 | STOCK OPTION EXERCISE |
Congress trades
1 trade in Coherus Oncology reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Shri Thanedar MI13 | Sold | Jan 23, 2023 | $15K–50K | Feb 9, 2023 |
See a number that looks wrong?